WO2024036184A3 - A human vh-based scaffold for the production of single domain antibodies and their use - Google Patents
A human vh-based scaffold for the production of single domain antibodies and their use Download PDFInfo
- Publication number
- WO2024036184A3 WO2024036184A3 PCT/US2023/071893 US2023071893W WO2024036184A3 WO 2024036184 A3 WO2024036184 A3 WO 2024036184A3 US 2023071893 W US2023071893 W US 2023071893W WO 2024036184 A3 WO2024036184 A3 WO 2024036184A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- human
- production
- single domain
- domain antibodies
- based scaffold
- Prior art date
Links
- 108010003723 Single-Domain Antibodies Proteins 0.000 title abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
- C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Provided herein are a human VH-based scaffold for the production of single domain antibodies and their use.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263396782P | 2022-08-10 | 2022-08-10 | |
US63/396,782 | 2022-08-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2024036184A2 WO2024036184A2 (en) | 2024-02-15 |
WO2024036184A3 true WO2024036184A3 (en) | 2024-04-18 |
Family
ID=89852469
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/071893 WO2024036184A2 (en) | 2022-08-10 | 2023-08-09 | A human vh-based scaffold for the production of single domain antibodies and their use |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024036184A2 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021048725A1 (en) * | 2019-09-12 | 2021-03-18 | Biotheus Inc. | Anti-pd-l1 single-domain antibody and derivatives and use thereof |
WO2021226405A1 (en) * | 2020-05-06 | 2021-11-11 | International Aids Vaccine Initiative Inc. | Covid-19 antibodies and uses thereof |
US20210355197A1 (en) * | 2018-10-22 | 2021-11-18 | International Aids Vaccine Initiative | Anti-hiv antibodies |
US20210395346A1 (en) * | 2020-06-22 | 2021-12-23 | Seoul National University R&Db Foundation | Stereotypic neutralizing vh clonotypes against sars-cov-2 rbd in covid-19 patients and the healthy population |
-
2023
- 2023-08-09 WO PCT/US2023/071893 patent/WO2024036184A2/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210355197A1 (en) * | 2018-10-22 | 2021-11-18 | International Aids Vaccine Initiative | Anti-hiv antibodies |
WO2021048725A1 (en) * | 2019-09-12 | 2021-03-18 | Biotheus Inc. | Anti-pd-l1 single-domain antibody and derivatives and use thereof |
WO2021226405A1 (en) * | 2020-05-06 | 2021-11-11 | International Aids Vaccine Initiative Inc. | Covid-19 antibodies and uses thereof |
US20210395346A1 (en) * | 2020-06-22 | 2021-12-23 | Seoul National University R&Db Foundation | Stereotypic neutralizing vh clonotypes against sars-cov-2 rbd in covid-19 patients and the healthy population |
Also Published As
Publication number | Publication date |
---|---|
WO2024036184A2 (en) | 2024-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021127404A8 (en) | Tricyclic pyridones and pyrimidones | |
TWD209028S (en) | Necklace | |
TWD209003S (en) | Necklace | |
TWD209525S (en) | Necklace | |
TWD210010S (en) | Necklace | |
TWD210040S (en) | Necklace | |
TWD207834S (en) | Necklace | |
TWD207843S (en) | Necklace | |
TWD207261S (en) | Necklace | |
TWD209988S (en) | Necklace | |
TWD209529S (en) | Necklace | |
TWD210027S (en) | Necklace | |
TWD209981S (en) | Necklace | |
TWD206377S (en) | Necklace | |
TWD206374S (en) | Necklace | |
TWD205323S (en) | Necklace | |
TWD204168S (en) | Necklace | |
TWD205921S (en) | Necklace | |
TWD208150S (en) | Necklace | |
TWD206376S (en) | Necklace | |
TWD205761S (en) | Soundbar | |
AU2020330570A8 (en) | Process of making CFTR modulators | |
TWD204171S (en) | Necklace | |
TWD205737S (en) | Necklace | |
TWD203906S (en) | Necklace |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23853496 Country of ref document: EP Kind code of ref document: A2 |